BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery

The collaboration between BioMed X and Novo Nordisk marks a significant step forward in the field of drug development, specifically targeting the oral delivery of therapeutic peptides. This partnership is set to explore novel oral formulation technologies designed to prolong the retention of tablets or capsules in the lower small intestine, thereby improving the absorption and bioavailability of peptide-based drugs. The initiative, titled 'Prolonged Retention of Oral Peptide Formulations in the Gut,' seeks to overcome the limitations posed by low intestinal permeability and rapid gastrointestinal transit, which have long hindered the effectiveness of conventional oral peptide formulations.

At the heart of this collaboration is the formation of a dedicated research team that will operate from BioMed X's facility in Heidelberg, Germany. The team's work is expected to lead to breakthroughs in oral formulation technologies, offering new hope for patients requiring peptide-based therapies. Interested researchers are encouraged to submit their project proposals via the BioMed X Career Space before the deadline on October 12, 2025.

Dr. Christian Tidona, CEO of BioMed X, expressed enthusiasm about the partnership, highlighting the potential impact on patients' lives through the development of orally available peptide drugs. Similarly, Stephen Buckley, Scientific Vice President at Novo Nordisk, underscored the company's commitment to pushing the boundaries of science through both internal and external innovation. This collaboration not only exemplifies the synergy between academia and industry but also sets a new benchmark for addressing some of the most pressing challenges in biomedical research.